acute myeloid leukemia

  •  

    How Would an Expert Manage His Own Acute Myelogenous Leukemia?

    With: Adam Asch, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks leukemia expert Adam Asch, MD, how he would handle his own case of acute myelogenous leukemia. Dr. Asch is Professor of Medicine and Nancy Johnson Records Chair of Oncology at the University of Oklahoma College of Medicine. Curious… Read more »

  •   George Lundberg, MD

    Written for oncology healthcare professionals, this article from the ASCO Educational Book covers targeted therapies and immunotherapies that are now available to improve the prospects of people with acute myeloid leukemia.

    .

  •   George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for acute myeloid leukemia.

    .

  •   George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic update with treatment options for all stages of acute myeloid leukemia is comprehensive and clear. (Free registration required, written with a physician audience in mind.)

    .

  •   George Lundberg, MD

    PDF from the National Comprehensive Cancer Network curated by Contributing Editor George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) has issued a 2020 edition of its Guidelines for Patients about acute myeloid leukemia.

    Go to full document published by the NCCN.

    .

  •   George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

    .

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A clinical trial showed substantial benefits of progression-free survival and overall survival for patients with a particular form of acute myeloid leukemia when treated by gilteritinib versus chemotherapy. However, the disease was still fatal.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Acute myeloid leukemia is a particularly difficult-to-treat form of leukemia. There are standard treatments, but it may be best for a patient to consider a clinical trial early on. This article from Medscape clearly specifies diagnostic and therapeutic options.

    .